Aval

Quick links to important sections

Aval

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aval

Aval and Valsartan: Identity and Pharmacological Classification

Property Description
Active Ingredient Valsartan (INN)
Form Oral solid (tablets/film-coated tablets)
Pharmacological Class Angiotensin II Receptor Blocker (ARB)
General Purpose Blood pressure management and cardiovascular support
Origin Synthetic compound

The medicine Aval is a pharmaceutical preparation containing the sole active ingredient known as Valsartan, a synthetic molecule that is the International Nonproprietary Name (INN) for the drug substance. It is officially classified as an Angiotensin II Receptor Blocker (ARB) and is primarily used as a prescription-only cardiovascular medicine for systemic administration.

Valsartan is clinically recognized for its high selectivity for the AT1 receptor, a key feature that underpins its specific action on the Renin-Angiotensin-Aldosterone System (RAAS). This mechanism identifies it as a potent Antihypertensive agent. The drug's efficacy is consistent across diverse adult populations, suggesting a broadly reliable effect for long-term management.

Composition, Form, and General Purpose

Aval is typically manufactured as an oral solid dosage form, delivered as tablets or film-coated tablets, and is always a single-ingredient product when referenced by the name Valsartan alone. This formulation facilitates the systemic absorption of Valsartan via the oral route, which is necessary for chronic management.

The general therapeutic purpose of this medicine is to promote and maintain effective blood pressure management. Valsartan is recognized as an essential medicine, confirming its importance as a core therapeutic option for cardiovascular conditions. The resulting vasodilation and regulated systemic pressure reduce the workload on the heart, contributing to sustained cardiovascular stability.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Aval?

Possible Side Effects and Safety Information for Aval

Aval (avalglucosidase alfa-ngpt, trade name Nexviazyme) has documented side effects and safety considerations derived from regulatory sources, primarily concerning hypersensitivity and infusion-related reactions.

Serious and Clinically Significant Risks

Severe Hypersensitivity and Infusion-Associated Reactions (IARs) are the most significant safety concerns. Patients have experienced life-threatening hypersensitivity reactions, including anaphylaxis. IARs, which can also be severe, include symptoms like chest discomfort, fever, chills, dizziness, trouble breathing, rash, or changes in blood pressure. These reactions require immediate monitoring and potential intervention.

Risk of Acute Cardiorespiratory Failure is noted for susceptible patients, particularly those with compromised cardiac or respiratory function or an acute underlying respiratory illness. Fluid volume overload during infusion may seriously exacerbate their status.

Common Adverse Reactions

The most frequently reported adverse reactions, occurring in more than 5% of patients in clinical trials, include:

System Organ Class Very Common (≥10% reported) Common (1% to 10% reported)
General Headache, Nasopharyngitis, Back Pain Fatigue, Chills, Pyrexia
Gastrointestinal Diarrhea, Nausea Vomiting, Abdominal Pain
Musculoskeletal Pain in Extremity Arthralgia (Joint Pain), Myalgia, Muscle Spasms
Skin Hypersensitivity Reactions Pruritus (Itching), Urticaria, Erythema

Population-Specific Considerations

Safety data is monitored for specific populations. A worldwide descriptive study is required by the FDA to assess the risk of pregnancy and maternal complications, adverse effects on the developing fetus and neonate, and adverse effects on the infant following exposure to Aval during pregnancy and/or lactation. Use in patients under 1 year of age has not been evaluated.

Overdose and Emergency Response

Overdose and When to Seek Help

The official overdose profile for Valsartan (Aval), an Angiotensin II Receptor Blocker, is defined by its potential to cause severe and life-threatening circulatory effects. This information is based on governmental regulatory documents and serves as guidance on emergency response.

The principal clinical sign of overdose is excessive hypotension (profoundly low blood pressure), which may be accompanied by heart rate variations such as tachycardia or bradycardia. Uncorrected, severe hypotension can progress to more serious outcomes, including depressed consciousness, circulatory collapse, and shock.

Overdose Risk and Management Official Regulatory Statement
Severe Outcomes Circulatory collapse and shock
Antidote Status No specific antidote is known
Removal Method Hemodialysis is unlikely to remove valsartan

Immediate medical attention is required for any suspected overdose, especially if signs of symptomatic hypotension or depressed consciousness are present. Management should be strictly symptomatic and supportive. Procedural steps described include placing the patient in a supine position and administering an intravenous infusion of normal saline solution if volume expansion is necessary to correct low blood pressure.

Therapeutic Uses of Aval

What Aval Treats: Main Uses and Benefits

Valsartan (Aval) is used across several major therapeutic domains, primarily addressing conditions characterized by symptoms related to systemic imbalance and heightened physiological stress. This medication is commonly used to help with long-term management of Systemic Hypertension in both adult and pediatric patients. It is also applied in managing Chronic Heart Failure, Post-Myocardial Infarction care focused on left ventricular support, and Diabetic Nephropathy for supportive management of kidney function.

The therapeutic benefit is foundational and preventative. It supports the patient during periods of heightened discomfort by easing the overall strain on the heart and circulatory system, and may assist with managing cardiovascular risk. This medicine is relevant in contexts involving chronic conditions where symptoms may intensify temporarily, such as fluid retention and breathing difficulty associated with heart failure.

“The medication assists with maintaining functional stability in conditions marked by increased physiological stress.”


Quick Fact: Relief for Systemic Strain Valsartan is primarily used to address the underlying strain caused by high blood pressure and cardiac inefficiency. It supports the maintenance of functional stability over time and helps ease the overall symptom load.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Valsartan (Aval) is subject to strict eligibility rules documented in official government regulatory labels. These rules define who is allowed to use the medicine, who must be excluded, and who requires restricted use.

Absolute Contraindications (Must Not Use)

  • Pregnancy: The medicine is contraindicated during the second and third trimesters due to risk of fetal injury. Use should be discontinued as soon as pregnancy is detected.
  • Severe Hepatic Conditions: Patients with severe hepatic impairment, biliary cirrhosis, or cholestasis must not use this medicine.
  • Hypersensitivity: Individuals with a known hypersensitivity to Valsartan or any component of the formulation.
  • Dual RAAS Blockade: Co-administration with Aliskiren is contraindicated in patients with diabetes mellitus or those with renal impairment (GFR < 60 mL/min/1.73 m^2).

Eligibility and Restrictions

  • Age-Related Eligibility: Aval is approved for use in adults and for the treatment of hypertension in pediatric patients from 6 to 16 years of age. Use is not recommended in children under 6 years of age.
  • Lactation: Use in breastfeeding women is not recommended as it is unknown if the drug is excreted in human milk.
  • Conditional Use: Caution and close monitoring are required for patients with pre-existing conditions affecting kidney function, such as renal artery stenosis, or for patients with volume/salt depletion, which must be corrected prior to treatment initiation.

What should I know about interactions with other medicines?

Aval Interactions with other medicines and products

Aval (avalglucosidase alfa-ngpt) is a recombinant enzyme replacement therapy and is not known to be metabolized by the cytochrome P450 enzyme systems or excreted intact by the kidney. Therefore, Aval is unlikely to be affected by, or to affect the plasma levels of, most commonly used prescription and over-the-counter medicines.

No dedicated drug-drug interaction studies have been conducted with Aval. Clinical data from population pharmacokinetic (PopPK) analyses did not identify other enzyme replacement therapies (such as alglucosidase alfa) as a factor significantly influencing the pharmacokinetics of Aval.

While direct drug interactions are not anticipated, patients are often pre-treated with certain medications before receiving an Aval infusion. These pre-treatment medicines, which may include antihistamines, antipyretics, and/or corticosteroids, are given to prevent or reduce the risk of infusion-associated reactions or hypersensitivity events.

Always inform your healthcare provider about all prescription and non-prescription products you are taking, including herbal supplements and vitamins, before starting therapy.

Mechanism of Action

Aval is a small-molecule inhibitor that acts by selectively binding to the active site of the enzyme Farnesyl Pyrophosphate Synthase (FPPS). This interaction is competitive and reversible, characterized by a high binding affinity for the substrate pocket. The binding of Aval prevents the normal catalytic activity of FPPS, which is responsible for the condensation of isopentenyl pyrophosphate (IPP) and dimethylallyl pyrophosphate (DMAPP) to form geranyl pyrophosphate (GPP) and farnesyl pyrophosphate (FPP).

By inhibiting FPPS, Aval disrupts the downstream production of farnesyl pyrophosphate (FPP) and subsequently geranylgeranyl pyrophosphate (GGPP). These two lipid intermediates are essential for the prenylation of small GTPases, including the Rho, Rac, and Rab families. The reduced availability of FPP and GGPP impairs the post-translational modification (prenylation) of these regulatory signaling proteins, leaving them in their inactive, unanchored cytosolic form.

The loss of prenylation and subsequent inactivation of Rho and Rac GTPases interrupts the signaling cascade required for the structural organization of the cytoskeleton in specific cell types. This results in the reduced formation of the ruffled border and a decrease in cellular adhesion and motility. This systemic effect shifts the balance of cellular turnover processes within the affected tissues.

Dosage and Administration Information

Valsartan (Aval) is administered exclusively via the oral route, primarily delivered as film-coated tablets in strengths ranging from 40 mg to 320 mg. The overall dosage regimen and frequency are defined by the specific official indication being addressed.

For the Systemic Hypertension regimen in adults, the standard involves administration once daily. The typical starting dose is either 80 mg or 160 mg, with the dose adjusted over a period of weeks up to a maximum daily intake of 320 mg. In contrast, usage for Chronic Heart Failure and Post-Myocardial Infarction care requires the total daily dose to be divided and taken twice daily (BID). For heart failure, therapy typically begins at 40 mg BID and may be titrated toward a target maintenance level of 160 mg BID.

Procedural instructions clarify that the medicine may be ingested with or without food. For consistent systemic exposure, the dose must be taken at the same time each day. If a scheduled dose is missed, administration guidance instructs the patient to resume the next dose at the regularly scheduled time without taking a double dose to compensate. Dosage adjustment is generally not required for older adults or in cases of mild-to-moderate renal or hepatic impairment. A specific, weight-based liquid suspension preparation is officially utilized for pediatric administration in hypertension.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aval


Evidence for use in Type 2 Diabetes Mellitus

Research has extensively examined the use of Aval in people with Type 2 Diabetes. This was studied for its role in managing blood sugar control. The research includes large, randomized controlled trials (RCTs) and observational studies, which involved adult populations, including those with and without a prior history of heart problems. Researchers monitored several outcomes, such as changes in the long-term blood sugar marker HbA1c, shifts in fasting sugar levels, and measurements related to body weight.

Research highlights changes measured during the study period. The trials describe patterns observed in the studied populations related to changes in HbA1c measurements and changes in body weight compared to a control group over the course of the studies. Evidence remains limited regarding the durability of these patterns over very extended periods, and long-term effects are not fully established beyond the initial trial follow-up.


Evidence for use in Heart Failure with Reduced Ejection Fraction (HFrEF)

Aval was studied for people diagnosed with Heart Failure with Reduced Ejection Fraction, regardless of whether they also had Type 2 Diabetes. The research involved major randomized controlled trials that studied how the condition evolved in adults with confirmed reduced heart pumping function (LVEF le 40%). The trials examined outcomes related to functional capacity, as well as major events like cardiovascular death and the need for hospitalization due to heart failure.

Trials describe patterns related to differences in the reported rate for the composite outcome of cardiovascular death or heart failure hospitalization across the follow-up period compared to the comparator arm. Evidence is limited for patients who have very recently experienced severe heart failure requiring hospitalization.


Evidence for use in Chronic Kidney Disease (CKD)

The use of Aval was observed in large, dedicated trials focusing on people with Chronic Kidney Disease (CKD), a condition involving difficulties related to kidney performance. Researchers examined outcomes including changes in the eGFR (a measure of kidney filtering ability) and the amount of protein in the urine (UACR), as well as progression to more advanced stages of kidney failure.

The findings describe patterns observed in the studies where participants was associated with differences in the reported rate of a composite endpoint, which included serious kidney-related events. Data for certain groups remain insufficient, particularly for individuals with the most advanced stages of CKD.

Frequently Asked Questions (FAQ)

Common questions about Aval (FAQ)

Q: How quickly does Aval usually start working after the first dose?

A: According to official product information, the initial blood pressure lowering effect begins approximately 2 hours after taking a single dose, with the maximum effect reached within about 6 hours. For a consistent and full blood pressure reduction, the full benefits are typically seen after about 4 weeks of consistent daily use.

Q: Can Aval cause tiredness or drowsiness?

A: Studies and official information indicate that fatigue (tiredness) is a common side effect reported in clinical trials. Less commonly, side effects like drowsiness and dizziness have also been reported. Patients are generally advised to understand how Aval affects them before engaging in activities that require full concentration.

Q: How long do the effects of a single dose of Aval typically last?

A: The effects of Aval are intended to last throughout the day. The drug's elimination half-life (the time it takes for half the drug to be eliminated from the body) is about 6 hours on average. The consistent blood pressure-lowering effect generally persists for a full 24 hours after a dose.

Q: Is Aval safe for people with kidney problems?

A: Dose adjustments are generally not required for individuals with mild or moderate kidney impairment. However, official prescribing information advises caution and monitoring for patients with severe kidney problems. Official prescribing information notes that co-administration with Aliskiren is contraindicated (must be avoided) in patients with certain degrees of kidney impairment.

Q: Is Aval considered a long-term or short-term medication?

A: Aval is generally intended for long-term management of chronic conditions, such as high blood pressure and heart failure. Clinical trials and regulatory data support its use for sustained cardiovascular risk reduction over an extended period.

Q: Why do some people take Aval in the morning and others at night?

A: Aval is prescribed to be taken either once or twice daily, depending on the medical condition being treated. Regulatory sources emphasize taking the medicine at the same time each day for consistent effectiveness. Research has indicated that the 24-hour efficacy of the drug remains stable regardless of whether the dose is taken in the morning or the evening.

Q: Can I drink alcohol moderately while taking Aval?

A: Official patient information advises caution regarding alcohol consumption while using Aval. Alcohol may intensify the drug's effect of lowering blood pressure, potentially leading to symptoms like dizziness, lightheadedness, or fainting. Any consumption of alcohol should be discussed with a healthcare provider.

Q: Is Aval safe to use during pregnancy (general concern, not specific case)?

A: Aval is not recommended for use during pregnancy. It is officially contraindicated in the second and third trimesters because of the known risk of injury or death to the developing fetus. Official guidance advises that use should be discontinued as soon as pregnancy is detected.

Q: Do children usually tolerate Aval well?

A: Aval is approved for treating high blood pressure in pediatric patients aged 6 to 16 years. Clinical data suggest that the safety profile and tolerance in children are generally similar to that observed in adults. However, the medication is not recommended for children under the age of 6.

Q: Is the onset of action for Aval immediate or gradual?

A: The onset of the blood pressure-lowering effect is gradual. Although the initial activity begins within about 2 hours, the maximum reduction in blood pressure usually takes 4 weeks of continuous therapy to be fully established.

Q: What are the storage requirements for Aval (e.g., room temperature, light)?

A: Official regulatory documents require Aval tablets to be stored at room temperature, specifically between 68 F and 77 F (20 C and 25 C). The product must be kept in its original container to protect it from environmental factors like moisture and direct light.

Q: What is the half-life of Aval?

A: The elimination half-life of the active ingredient in Aval (Valsartan) is approximately 6 hours on average. The half-life is the time it takes for the concentration of the drug in the blood to decrease by half.

Q: Is it normal to feel slightly dizzy when first starting Aval?

A: Yes, regulatory documents list dizziness or lightheadedness as common side effects when starting Aval or following a dose increase. This is typically related to the body adjusting to the blood pressure lowering effect of the medication.

Q: Does Aval interact with common pain relievers like ibuprofen?

A: Official information notes that caution is required when Aval is used with common pain relievers known as Nonsteroidal Anti-inflammatory Drugs (NSAIDs), which includes ibuprofen. This combination may reduce the effectiveness of Aval in lowering blood pressure and could increase the risk of worsening kidney function.

Q: Can elderly patients safely take Aval?

A: Regulatory information states that no initial dosage adjustment is typically required for elderly patients. However, studies indicate that the exposure to the drug may be higher and the half-life longer in the elderly compared to younger adults.

Q: Can Aval affect my ability to drive or operate machinery?

A: Because Aval can cause side effects such as dizziness or lightheadedness, it may affect concentration and reaction time. Patients are generally advised to be cautious regarding driving or operating heavy machinery until the effect of the medicine is understood.

Q: Does Aval have a high risk of addiction or dependency?

A: No. Official regulatory classifications confirm that Aval is not scheduled as a controlled substance by the DEA and does not carry a risk of addiction or dependency.

Q: How long does it take for Aval to be completely cleared from the body?

A: The elimination half-life of Aval is approximately 6 hours. It generally takes about five half-lives for a drug to be considered effectively cleared from the body.

Q: Can Aval be crushed or chewed, or should it be swallowed whole?

A: The tablets are intended to be swallowed whole according to official patient information. They should not be broken, crushed, or chewed. Alternative liquid formulations are available for patients who have difficulty swallowing.

Q: Can Aval cause changes in mood or behavior?

A: Adverse event data for the active ingredient in Aval have listed rare or uncommon reports of side effects related to mood, including depression, insomnia, or mood swings. These changes are reported in adverse event data, and patients generally report such occurrences to their healthcare provider.

Q: Can I take other over-the-counter cold medicines with Aval?

A: Patients are generally encouraged to consult with their healthcare provider regarding the use of over-the-counter cold, cough, or pain medications to ensure there is no risk of interaction. Some cold remedies contain ingredients that can affect blood pressure or interact with Aval (e.g., NSAIDs).

Q: How long is the typical course of treatment with Aval?

A: Aval is indicated for the treatment of chronic conditions such as hypertension and heart failure. For these conditions, the typical course of treatment is long-term and continuous, unless a healthcare provider directs a change in therapy.

Q: Can Aval worsen underlying anxiety?

A: Adverse event reports for the active ingredient have rarely listed fear or nervousness as a side effect. Its specific effect on pre-existing anxiety is not usually detailed in regulatory labels, but patients generally report any significant changes to their healthcare provider.

Q: Are there different strengths or formulations of Aval?

A: Yes, Aval (Valsartan) is available as oral film-coated tablets in a range of strengths. A weight-based liquid suspension formulation is also officially available and utilized for specific patient groups, such as some children with hypertension.

Q: Why do some forums discuss a 'weaning off' period for Aval?

A: Abruptly stopping any blood pressure medication, including Aval, can cause a rapid or sharp increase in blood pressure. Therefore, discontinuation of Aval is typically performed under the supervision of a healthcare provider, who may recommend a gradual reduction.

Q: Can taking Aval affect sleep patterns?

A: Adverse event reports for the active ingredient in Aval have listed insomnia (difficulty sleeping) as an uncommon side effect. Patients generally discuss any changes in their sleep patterns with their healthcare provider.

Q: How often do patients need follow-up appointments when taking Aval?

A: Official patient information advises visiting the healthcare team for regular follow-up checks to monitor progress and adjust treatment as necessary. The frequency of these appointments is determined by the specific condition being treated and the patient's individual needs.

Q: What happens if I stop taking Aval suddenly?

A: Abruptly stopping Aval, like other medications for high blood pressure, can cause a rapid increase in blood pressure, potentially raising the risk of serious cardiovascular events. Discontinuation is typically performed only under the supervision of a healthcare provider.

Q: Are there any known drug-drug interactions with common antidepressants and Aval?

A: Interactions are possible with certain types of antidepressants. For example, some regulatory information notes that Tricyclic Antidepressants (TCAs) may have an additive blood pressure lowering effect when taken with Aval. It is important to inform a healthcare provider about all prescription and non-prescription medicines being taken.

How should Aval be stored and disposed of?

Storage and Handling Requirements

Official regulatory documents require that Aval (valsartan) tablets be stored according to specific conditions to maintain their stability and effectiveness:

  • Temperature: Store the product below 30 C.
  • Protection: Keep the tablets in their original container to protect them from environmental factors, such as light and moisture.
  • Child Safety: The medicine must be kept out of the sight and reach of children to prevent accidental ingestion.

Official Disposal Instructions

Unused or expired Aval must be disposed of according to national and local requirements. Regulatory guidance emphasizes that the medicine must not be disposed of via wastewater or regular household waste. Instead, patients should utilize established drug take-back programs or authorized collection points for proper pharmaceutical waste management.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Aval found in:

A-Z Index: